Distress and Its Determinants in 820 Consecutive Melanoma Patients by Markus Reitmajer, Petra Riedel, Claus Garbe, Norbert Schäffeler, Thomas K. Eigentler, Andrea Forschner

Get full text

Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 by Markus Reitmajer, Lena Nanz, Nina Müller, Ulrike Leiter, Teresa Amaral, Valentin Aebischer, Lukas Flatz, Andrea Forschner

Get full text

Determining the role of basophil activation testing in reported type 1 allergy to beta-lactam antibiotics by Markus Reitmajer, Antonia Strauss, Christian Klinger, Maximiliane Maaß, Wolfgang E. Kempf, Wolfgang E. Kempf, Joerg Fischer, Joerg Fischer, Manfred Kneilling, Manfred Kneilling, Sebastian Volc, Sebastian Volc

Get full text

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation by Julia Forschner, Julia Huynh, Christopher Schroeder, Sorin Armeanu-Ebinger, Olga Seibel-Kelemen, Axel Gschwind, Irina Bonzheim, Thomas K. Eigentler, Teresa Amaral, Stephan Ossowski, Lukas Flatz, Claus Garbe, Andrea Forschner, Markus Reitmajer

Get full text